Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

March 10, 2023

1 minute read

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Analyst Cuts Playboy Parent’s Price Target As Inflation Woes Hit Earnings

August 10, 3:13 PM

Chardan Capital analyst Brian Dobson reiterated a Buy rating on PLBY Group Inc (NASDAQ:PLBY) and lowered the price target to $9 from $13…

August 11, 3:07 PM

Zevia PBC (NYSE:ZVIA) reported second-quarter FY22 sales growth of 33% year-on-year to $45.54 million, beating the consensus of $42.17 million. Unit…

July 25, 3:00 PM

Over the past 3 months, 4 analysts have published their opinion on Ooma (NYSE:OOMA) stock. These analysts are…

February 6, 11:56 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).